Results 131 to 140 of about 78,276 (237)

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice

Human Genomics
Background Community pharmacists must be well-equipped to advance pharmacogenomics services. Nevertheless, limited data is available regarding pharmacists' knowledge and attitudes toward pharmacogenomics testing.
Azza Ramadan, Anan S. Jarab, Ahmad Z. Al Meslamani   +2 more
doaj   +1 more source

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 445-456, February 2026.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato, Samantha Perfler, Diletta Pasin, Elena Peruzzi, Michael Woodcock, Henry Thomas, Rebecca Goodall, Simon J. Patton, Erika Cecchin   +8 more
wiley   +1 more source

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

Pharmacogenomics and Personalized Medicine, 2016
Jai N Patel Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision ...
Patel JN
doaj  

Pharmacogenomics and Big Data in medical oncology: developments and challenges

Therapeutic Advances in Medical Oncology
Medical oncology, through conventional chemotherapy as well as targeted drugs, remains an important component of cancer patient management, particularly for systemic disease.
Loredana G. Marcu, David C. Marcu
doaj   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Progress in the Direct Application of Pharmacogenomics to Patient Care: Sustaining innovation [PDF]

, 2007
Felix W. Frueh, Lawrence J. Lesko, Gilbert J. Burckart   +2 more
openalex   +1 more source

Pharmacogenomic screening for agranulocytosis and efficacy with clozapine [PDF]

, 2023
Mujeeb U. Shad
openalex   +1 more source

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Maliha Malik, Hammad Amjad, Khadija Malik, Muddassir Syed Saleem, Shanzay Akhtar, Muslehuddin Paracha, Mobeen Abid, Nabahat Shafi, Ahmed Asad Raza, Abedin Samadi, Samar Abbas Jaffri   +10 more
wiley   +1 more source

Pharmacogenomics of Colorectal Cancer: From Discovery to Clinical Implementation and Back [PDF]

, 2017
Erika Cecchin
openalex   +1 more source